厄贝沙坦对2型糖尿病肾病微量白蛋白尿的治疗作用

目的 观察厄贝沙坦合并常规治疗方法治疗2型糖尿病肾病微量白蛋白尿患者的效果.方法 将我院80例2型糖尿病肾病微量白蛋白尿患者,随机平均分为两组,在常规降糖、抗凝、降脂、低蛋白饮食治疗的基础上,治疗组:加用厄贝沙坦;对照组:常规治疗未加厄贝沙坦.所有病例于治疗前及治疗3个月、6个月时抽血测定空服血糖(FBG)、餐后血糖(PBG)、内生肌酐清除率(Ccr)、血尿素氮(BUN)、24 h Upro、UAER、ACR检测,然后对治疗前后两组分别进行对比分析.结果 治疗组2型糖尿病肾病微量白蛋白尿患者,在常规降糖、抗凝、降脂、低蛋白饮食治疗的基础,上加用厄贝沙坦,治疗3个月、6个月后24 h Upro、UAER、ACR明显要好于对照组.结论 厄贝沙坦治疗2型糖尿病肾病微量白蛋白尿临床疗效显著可靠.

Irbesartan in type 2 diabetic nephropathy treatment of microalbuminuria

Objective To observe irbesartan combined conventional therapy in treating type 2 diabetic patients with microalbuminuria results. Methods 80 cases in hospital with type 2 diabetic patients with microalbuminuria were randomly divided into two groups, in the conventional hypoglycemic, anticoagulant, lipidlowering, low-protein diet on the basis of the treatment, the treatment group:plus Heuberger losartan; control group: conventional treatment without irbesartan. All patients before treatment and at 3 months of treatment, at 6months for blood glucose determination of flight(FBG), postprandial blood glucose(PBG), endogenous creatinine clearance rate(Ccr), blood urea nitrogen(BUN), 24 h Upro, UAER, ACR test, then the two groups before and after treatment were analyzed. Results The treatment group of type 2 diabetic nephropathy in patients with microalbuminuria, in the conventional hypoglycemic, anticoagulant, lipid-lowering, low-protein diet based treatment, on the plus irbesartan, treatment for 3 nonths, 6 months after the 24 h Upro, UAER, ACR significantly better than the control group. Conclusion Irbesartan treatment of type 2 diabetic microalbuminuria in clinical efficacy and reliable.